Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 7/20 | 0.54 |
| ▸ | CLK2 | P49760 | 6/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.54 |
| ▸ | LCK | P06239 | 6/20 | 0.54 |
| ▸ | MET | P08581 | 6/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.54 |
| ▸ | RET | P07949 | 4/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.54 |
| ▸ | GSK3B | P49841 | 4/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.54 |
| ▸ | GSK3A | P49840 | 4/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.54 |
| ▸ | CSF1R | P07333 | 4/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.54 |
| ▸ | PRKACA | P17612 | 3/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901292 | 0.78 | MAP4K4 (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL14293291 | 0.78 | MAP4K4 (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL3868631 | 0.78 | MAP4K4 (0.57) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL15743366 | 0.78 | KDR (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL868188 | 0.75 | MAPT (0.60) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL13019311 | 0.75 | HTT (0.55) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL15743285 | 0.75 | MAP4K4 (0.50) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL18360948 | 0.73 | MAP4K4 (0.49) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL18590960 | 0.73 | MAP4K4 (0.49) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL6926673 | 0.73 | KDR (0.49) | KDRMAP4K4MAP4K2CLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| CN-112236429-B | Heteroaryl compounds useful as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236429-A | Heteroaryl compounds as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | KDR 973/4885MAP4K4 64/4885MAP4K2 12/4885 |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDR 1533/4885MAP4K4 1013/4885MAP4K2 357/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | KDR 3297/4885MAP4K4 265/4885MAP4K2 244/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | KDR 3297/4885MAP4K4 265/4885MAP4K2 244/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | KDR 1367/4885MAP4K4 709/4885MAP4K2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.